Intellectual Property

Inovio has protected its leading position in the biopharmaceutical sector, particularly in electroporation delivery technology and DNA vaccine technology, through establishing and maintaining a comprehensive intellectual property portfolio.

Inovio's patents encompass both pharmaceutical and electroporation delivery technology.

Inovio's pharmaceutical patents cover its synthetic consensus antigens and DNA vaccines. In addition, Inovio has broad patent coverage over its small molecule and protein based therapeutics that include anti-inflammatories, HIV inhibitors, and anti-cancer agents.

Inovio's electroporation technology covers five broad, medically relevant "indication" categories including:

• gene therapy/delivery (including vaccination with expressible vectors)
• oncology
• vascular administration (e.g. by catheter)
• transdermal administration (including delivery of substances for cancer, gene therapy, and cosmetic applications)
• ex vivo administration (e.g. by electroporation of cells outside the body and introducing the created cells to the patient)

back to top